ZTS250117C75000
- 0.00
- 0.000.00%
Zoetis Newsroom
Weekly Buzz: So far, Santa is Letting us Down
Friday Market Pulls Back, Led by Mag Seven Decline | Live Stock
Zoetis Inc. (ZTS): A Bull Case Theory
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Here's Why Zoetis (ZTS) Gained But Lagged the Market Today
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
Earnings Are Growing at Zoetis (NYSE:ZTS) but Shareholders Still Don't Like Its Prospects
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
Dow Breaks Downward Spiral, with FOMC Rate Cut on Deck | Live Stock
Leerink Partners Maintains Zoetis(ZTS.US) With Buy Rating, Maintains Target Price $215
Analysts' Opinions Are Mixed on These Healthcare Stocks: Zoetis (ZTS), Walgreens Boots Alliance (WBA) and Bicycle Therapeutics (BCYC)
Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today
Zoetis Dips as FDA Cites Adverse Events Linked to Canine Pain Therapy Librela
Tuesday Tech Pull Back After Nasdaq and Bitcoin Record | Live Stock
FDA Warns About Dangers of Dog Pain Drug -- WSJ
BofA Securities Maintains Zoetis(ZTS.US) With Buy Rating, Maintains Target Price $210
Positive Outlook on Zoetis's Stock Despite FDA Review of Librela
Another Week, Another Index Record | Lkive Stock
4 Stocks in Focus That Declared Dividend Hikes Amid Market Volatility